Shares of Bristol Myers Squibb Co. BMY inched 0.67% higher to $53.96 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.90% ...

Bristol-Myers Squibb (BMY) stock shows potential for growth with recent FDA approval and strong oncology portfolio, but faces ...

On Wednesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $53.76 which represents a slight increase of $0.86 or 1.63% from the prior close of $52.9. The stock opened at ...

Dividend investing can create substantial passive income over time. A conservative example illustrates this potential: ...

The Health Care Select Sector SPDR Fund ETF (NYSEARCA:XLV), tracking the healthcare companies under S&P 500, rose 6.27% in ...

IGM Biosciences Inc.'s stock tumbled 14% Tuesday, as analysts weighed in with dismay on the company's pivot away from oncology to a focus on autoimmune diseases, with at least two opting to lower ...

The latest health news highlights include Kailera Therapeutics' $400 million funding, potential CVS Health restructuring, ...

Dividend investing has become increasingly popular over time, as generating regular income remains a key focus for investors.

Leerink Partners analyst David Risinger has maintained their neutral stance on BMY stock, giving a Hold rating on September 26. David Risinger ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

In the year’s fourth-largest deal, Prime Medicine Inc. will collaborate with Bristol Myers Squibb Co. (BMS) in a research collaboration and license agreement totaling $3.61 billion. The two companies ...

Prime Medicine (PRME) shares rallied 15% Monday after the company announced a collaboration with Bristol Myers (BMY), which ...